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Abstract
Background: Ethiopia has been providing free Antiretroviral Treatment (ART) since 2005 for HIV/AIDS patients. ART
improves survival time and quality of life of HIV patients but ART treatment outcomes might be affected by several
factors. However, factors affecting treatment outcomes are poorly understood in Ethiopia. Hence, this study assesses
treatment outcomes and its determinants for HIV patients on ART in selected health facilities of Kembata and
Hadiya zones.
Methods: A retrospective cohort study was conducted on 730 adult HIV/AIDS patients who enrolled antiretroviral
therapy from 2007 to 2011 in four selected health facilities of Kembata and Hadiya zones of Southern Ethiopia.
Study subjects were sampled from the health facilities based on population proportion to size. Data was abstracted
using data extraction format from medical records. Kaplan-Meier survival function was used to estimate survival
probability. Cox proportional hazards regression model was used to identify factors associated with time to death.
Result: Median age of patients was 32.4 years with Inter Quartile Range (IQR) [15, 65]. The female to male ratio of
the study participants’ was 1.4:1. Median CD4 count significantly increased during the last four consecutive years of
follow up. A total of 92 (12.6 %) patients died, 106(14.5 %) were lost to follow-up, and 109(15 %) were transferred
out. Sixty three (68 %) deaths occurred in the first 6 months of treatment. The median survival time was 25 months
with IQR [9, 43]. After adjustment for confounders, WHO clinical stage IV [HR 2.42; 95 % CI, 1.19, 5.86], baseline CD4
lymphocyte counts of 201 cell/mm3 and 350 cell/mm3 [HR 0.20; 95 % CI; 0.09−0.43], poor regimen adherence
[HR 2.70 95 % CI: 1.4096, 5.20], baseline hemoglobin level of 10gm/dl and above [HR 0.23; 95 % CI: 0.14, 0.37] and
baseline functional status of bedridden [HR 3.40; 95 % CI: 1.61, 7.21] were associated with five year survival of HIV
patients on ART.
Conclusion: All people living with HIV/AIDS should initiate ART as early as possible. Initiation of ART at the early
stages of the disease, before deterioration of the functional status of the patients and before the reduction of CD4
counts and hemoglobin levels with an intensified health education on adherence to ART regimen is recommended.
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Background
An estimated 34.0 million adults worldwide were living
with Human Immunodeficiency Virus (HIV) and of these
2.5 million were newly infected with the virus and 1.7 mil-
lion died of HIV/ Acquired Immune Deficiency Syndrome
(AIDS) in 2011 [1]. In Sub–Saharan Africa, more than
23.5 million people were living with HIV, 1.8 million be-
come newly infected and 1.3 million died of (AIDS) at the
end of 2011 [1].
HIV management is currently in an era of effective
ART. In the last 29 years, modern drug discovery and
have development has transformed HIV-1 disease into a
treatable chronic infectious disease [2]. In 2009 alone,
1.2 million people received ART for the first time world-
wide, an increase in the number of people receiving
treatment by 30 % in a single year. Overall, the number
of people receiving therapy has grown 13-fold, more
than five million people in low and middle-income
countries, since 2004 [3].
Since 2005, the Ethiopian government in collabor-
ation with its partners has been providing free anti-
retroviral drugs for eligible HIV/AIDS patients in
order to reduce epidemics and improve the quality
of life for those living with the virus. Of the more
than 1.2 million individuals living with the virus,
397,818 were eligible in 2010/11 for antiretroviral
treatment [4]. There were about 743 health facilities
that provide ART for 333,434 HIV/AIDS patients in
2010/11 [4].
According to the 2011 Ethiopian Demographic and
Health Survey, the national prevalence of adult HIV was
2.4 and 1.0 % in SNNPR [5]. Regarding the distribution,
urban areas had much higher prevalence (4.0 %) than
rural areas (0.6 %). Moreover, the prevalence was higher
among females (1.9 %) than males 1.0 % [5].
The use of antiretroviral medicines has dramatically
reduced AIDS related illnesses and death in countries
where these drugs are widely accessible [6].
HIV incidence has fallen by more than 25 % be-
tween 2001 and 2009 in 33 countries. Of these
countries, 22 are from sub-Saharan Africa [3]. Early
reports from ART programs in resource-limited set-
tings have been promising, with virological efficacy
comparable to industrialized countries [7]. Neverthe-
less, mortality has been high, particularly during the
first months after initiating ART [7, 8]. While evi-
dences have proven that ART improves the survival
time and quality of life of HIV patients, several clin-
ical and socio demographic factors contributing to
this high mortality and poor treatment outcome are
not well understood in Ethiopia. Hence, this study
was designed to investigate the treatment outcomes
and its determinants for HIV patients on ART in se-
lected health facilities of Kembata and Hadiya zones,
Southern Nations, Nationalities and Peoples Region,
Ethiopia.
Methods
Study area and period
The study was conducted in four selected health facilities
from Kembata and Hadiya zones, South Nations, National-
ities and Peoples Region [SNNPR], Ethiopia. SNNPR is one
of the largest regions in Ethiopia, accounting for more than
10 percent of the country’s land area and the current popu-
lation is approximately 17 million with an average house-
hold size of 4.8 in 2007. More than 91 percent of the
SNNPR population lives in rural areas [9]. The mid-2010
population was estimated at nearly 17,745,000 [10]. The
region is divided into 13 administrative zones. But, this
study was conducted in two Health Centers and two
Zonal Hospitals of Kembata and Hadiya zones. Kembata
Zone has ten districts and an estimated total population
of 1.2 million. It has one zonal hospital, 30 functional pub-
lic health centers and 262 health posts among which nine
health centers and one zonal hospital are providing ART
services for 986 ART patients [11]. Similarly, Hadiya Zone
has 11 districts with an estimated total population of 1.5
million. It has one zonal hospital, 37 functional public
health centers and 282 health posts among which ten
health centers and one zonal hospital are providing ART
service for 2367 ART patients. The health service cover-
age in the two zones is 100 % [12]. The study was con-
ducted from January to February, 2012.
Study design
A retrospective cohort study was conducted on people
living with HIV/AIDS enrolled for ART services in two
Health Centers and two Zonal Hospitals of Kambata and
Hadiya zones from 2007 to 2011.
Target and study population
The target population was all adult HIV positive patients
enrolled for ART services in SNNPR and the study
population was all adult HIV positive patients enrolled
on ART from December 2007- December 2011 in four
selected health facilities of Kembata and Hadiya zones of
SNNP Region. All HIV/AIDS patients who were 15 years
old and above and enrolled on ART program for at least
two clinical visits in the selected health facilities were in-
cluded in the study. Patients who started treatment in
other places and with incomplete baseline CD4 counts
and basic personal information such as hemoglobin level
and age were excluded.
Sample and sampling technique
Purposive sampling was used to include the two zones
from the 13 zones of SNNPR. Currently there are 20
health facilities providing ART services in the study area.
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Among these, six health facilities (two hospital and four
health centers) were eligible for this study. Eligible
health facilities were stratified into hospital and health
centers in each study zone and then one hospital was in-
cluded from each zone. Since each zone had only one
hospital, the two hospitals namely Durame Hospital
from Kembata and Hossana Hospital from Hadiya were
included as study sites. Among the two eligible health
centers from each zone, the health center with the high-
est number of HIV patients (case load) on ART was se-
lected. Thus, one hospital and one health center were
selected from each zone to be included in the study. Fi-
nally all eligible patients (730) on ART from the four
health facilities were included as study subjects.
Standard and operational definition
The main outcome variables were death and time to
death in any of the five years follow up period. Second-
ary outcome variable (undesirable outcome) was time
when patient was lost to follow up, stopped or dropped
out any of the five years follow up period. Survival time
was defined as the length of time between ART initiation
and death/censure. The predictor (covariate) variables
included in the model were socio demographic factors
(age, sex, marital status, level of education, religion, resi-
dence, employment status, spouse health and ART en-
rollment condition), past and new opportunistic illness,
WHO clinical stage, baseline CD4 cells count, baseline
weight, hemoglobin, drug regimen, functional status, ad-
herence to HIV medication, attendance of HIV related
training, HIV prophylaxis, type of facility (health center,
hospital), tobacco smoking, alcohol drinking and use of
other substances.
Data collection tools and procedures
A structured data extraction format was adopted from
ART intake and follow up forms of ART clinics. Six
nurses were recruited and one for each health center
and two for each hospital were assigned as data colla-
tors. Data was collected retrospectively from all eligible
medical records of adult HIV/AIDS patients on ART
from ART in take form and ART follow up forms.
Data management and statistical analysis
Data was entered, cleaned and coded and checked for
missing values, outliers and inconsistencies using SPSS
Version 16. To ensure data quality, data collectors were
trained, pre-test was carried out at a health center with
similar setting to the study health facilities, filled-in
forms were checked for completeness and accuracy and
corrected on daily basis before leaving the health facil-
ities and 10 % of data were re-entered and discrepancies
reviewed by an independent person. Data analysis was
carried out with STATA 11.
Descriptive statistical methods were used to summarize
the socio-demographic and clinical characteristics of the
study participants. The survival time was calculated in
months using the time interval between date of ART initi-
ation and 1) date of event (death) for events, 2) date of
transfer for transferred out (TO), 3) first date of the first
missed appointment for lost cases and 4) the date in
which patient completed the 60 months (five years) follow
up. For survival analysis two scenarios were considered
separately, a real-case assumption (confirmed dead cases
were used as events) and a worst-case assumption (lost
cases were also considered as events). Descriptive survival
statistical analysis (Kaplan-Meier) was used to estimate
survival probability after ART initiation. Cox proportional
hazards models were used to examine baseline factors
associated with time to death. To evaluate the effects of
covariate on patient survival, the Wald test was used to
define the variables to be entered into the Cox propor-
tional hazards model. Factors that were associated with
time to death at 25 % significant level in the bivariate
analysis were included in the final Multivariate analysis.
Then important predictor variables were identified by
fitting the stepwise Cox’s proportional hazard model to
the data set. The results of the final model were
expressed in terms of Hazard Ratio (HR) and 95 % con-
fidence intervals (CI) and statistical significance was
declared if the p-value is less than 0.05. The presence
of potential confounding factors or interaction were di-
agnosed and treated accordingly. Finally Cox propor-
tional hazards model goodness of fit were assessed by
using Cox-Snell residual and Harrell’s Concordance
statistic test and the model was fitted accordingly to
predicted response variable (Fig. 5).
Ethical clearance was obtained from the Institutional
Review Board of the College of Health Sciences of
Mekelle University. No information obtained from the
medical records was disclosed to any third person. Pa-
tient identification variables such as name were not used
in the study. This study did not inflict harm on or ex-
pose HIV/AIDS patients to unnecessary risk as a result
of reviewing their medical records.
Result
Out of, 730 patients included in the analysis, 270(37 %)
were initiated on ART in 2007, While 134(18 %),
160(22 %) 81(11 %) and 85(12 %) were initiated in 2008,
2009, 2010 and 2011 respectively. The study findings re-
vealed that 429 (59 %) study subjects were females. The
median age of the patients was 30 with IQR [26, 37]
years. Of the study subjects, two-third of them were had
no formal education or completed primary education at
the time of initiation of their ART treatment. Almost
62 % of the patients were unemployed at the time of ini-
tiation of ART and 51.4 % of the patients were enrolled
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from urban districts. From a total of 730 patients,
178(24.4 %) drink alcohol, 98 (13.4 %) use other sub-
stances such as Khat and Shisha and 94 (12.9 %) smoke
tobacco at initiation of ARV treatment (Table 1). From
730 patients, 481(65.9 %) had opportunistic infections at
the time of treatment initiation and 196(26 %) patients
developed opportunistic infections after initiation of
ARV treatment.
Regarding the functional status of the patients, 495
(68 %) were working, 194 (26.6 %) ambulatory and
39(5.4 %) bedridden at the time of the start of ARV
treatment. Moreover, 413 (57 %) were in WHO stage III,
148(20.4 %) in stage II, 101 (14 %) patients were in stage
I and 62 (8.6 %) patients were in stage IV at the time of
ART initiation. Meanwhile, median [IQR] CD4 count
was 151 [78, 224] cells/mm3. Six hundred seventy five
(92.5 %) patients had good, 18(2.4 %) fair and 37(5.1 %)
poor adherence to recommended ART regimen (Table 2).
Median weight [IQR] of patients at baseline was 51.5
[46 57.2] kg and had increased to 55 kg and
56.75 kg(p = 001) at first 6 and 12 months follow up,
respectively (Fig. 1). Similarly, CD4 count significantly
increased over the last four consecutive years of fol-
low up. The median CD4-cell count at ART initiation
was 151 cells/mm3 which increased to 299 cells/mm3
at 6 months, 353 cells/mm3 at 12 months, 410 cells/
mm3 at 24 months, 464.5 cells/mm3 at 36 months,
497 cells/mm3 at 48 months and 488.5 cells/mm3 at
60 months of follow up (Fig. 2).
Descriptive survival analysis of patients during the follow
up period
The median [IQR] follow-up time was 25 [9, 43]
months. A total of 92(12.6 %) patients died in the five
years follow up period after initiation of ARV treatment.
Among these, 63 (68 %) deaths occurred in the first
6 months of treatment, 70 (76.1 %) deaths occurred
within one year follow up, 14(15.2 %) between one and
two years of follow up and the rest 8 (8.7 %) deaths oc-
curred between third and fifth years of follow up. Over-
all, 106 (14.5 %) patients were lost to follow-up and
109(14.9 %) were transferred out to other heath facilities
for treatment. The mortality rate during the follow-up
period was 4/1000 person-years. Survival function
showed that the probability of surviving for real and
worst case assumptions was 0.83 and 0.64, respectively
(Table 3). The survival function estimate graphs (Fig. 3)
declined sharply at first six months follow up and then
tailed off gradually. On the other side, the hazard esti-
mate graphs (Fig. 4) sharply increased at the first six
months of follow up. The initial sharp decline shows
that there was high risk of dying during the first six
months of follow up. The relatively long right tail was
due to the few subjects who had long survival times.
The minimum value of the survivorship function was
not zero since the largest observed time was a censored
observation.
Bivariate and multivariate analysis
Bivariate analysis of the factors revealed that the risk of
death in five years follow up was associated with sex,
spouse treatment status, tobacco smoking, other sub-
stance use, Tuberculosis (TB) status before initiation of
ART, OIs after initiation of ART, TB after initiation of
ART, functional status, WHO clinical stage, hemoglobin,
baseline CD4 cells count, baseline weight, baseline drug
regimen and regimen adherence. Factors that were asso-
ciated with time to death at 25 % significant level in the
bivariate analysis were included in the final multivariate
analysis. According to the multivariate Cox model, the
risk of death for patients with two or more opportunistic
infections after initiation of ART was roughly three fold
(hazard ratio, 3.353; 95 % CI, 1.462– 7.691) as compared
with patients who had no opportunistic infection follow-
ing the initiation of ART. Similarly, those with WHO
stage III and IV at ART initiation had increased risk of
death [hazard ratio (HR) 2.01, 95 % CI: 1.02,4.35; HR
2.42, (95 % CI: 1.19, 5.86, respectively], when compared
with WHO stage I. However, those with 51–200 cells/mm3,
201–350 cell/mm3 and above 350 cell/mm3 baseline
CD4 cell counts reduce the risk of death by 0.26
[95 % CI; 0.15, 0.45], 0.198 [95 % CI; 0.09, 0.43] and
0.12 [95 % CI; 0.02, 0.91], respectively as compared
to patients with less than 51 cell/mm3 CD4 counts.
Patients with hemoglobin level of 10 g/dl and above
at initiation of ART had reduced a risk of death reduced
by 0.22 [HR 0.22, 95 % CI: 0.14, 0.37] as compared to
those whose hemoglobin level was less than 10 g/dl. The
risk of death was 2.7 times higher for patients with poor
regimen adherence (HR: 2.70, 95 % CI: [1.40, 5.20] as
compared to patient who had good regimen adherence.
Similarly, patients with ambulatory and bedridden func-
tional status had higher risk of dying (HR: 1.79; 95 % CI:
[1.05, 3.07]) and (HR: 3.40, 95 % CI: [1.61, 7.21]), respect-
ively as compared with those working functional status at
baseline (Table 4).
Discussion and conclusions
The proportion of female patients was significantly
higher than the one of male patients. This might be due
to the fact that women by their nature are highly vulner-
able to HIV infection than their counterparts. Moreover,
women may be more often diagnosed than men due to
high frequency of testing for women as part of PMTCT
program. Similar findings were reported from Hawassa
referral hospital in SNNPR, Ethiopia [13]. Moreover, the
findings of this study coincide with other studies con-
ducted in Africa in terms of sex proportionality [14, 15].
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About 12.2 % of patients died during the five years fol-
low up period and 68 % of the deaths occurred within
the first six months of follow up. This was higher than
11.2 % death after 24 months of follow up reported in
the retrospective longitudinal study from Ethiopia [16].
The overall death in the five year follow up study was
lower compared to 29.7 % death after three years of fol-
low up from Cameroon [17] and 28.5 % from Tanzania
[18] who died after five years of ART follow up. How-
ever, the total death in our finding was slightly higher
than the two years follow up study conducted in Shasha-
mene and Assela Hospitals [10.2 %] from Ethiopia [19].
This could be explained by the fact that our study was
based on five years of survival compared to the two
years of survival analysis [19].
The higher mortality in the first few months of therapy
in our set up was similar to other studies reported from
different African countries [17–20]. This may partly be
explained by the fact that most of the patients had CD4
count less than 200 cells/mm3 at the time of ART initi-
ation and were at an advanced WHO stages [III and IV].
More than half of the patients did not attend any kind
of HIV related education and had no idea about prophy-
laxis. Besides, 48.6 % of them were from rural areas,
where access to information and Volunteer counseling
and testing services were highly limited during initiation
of ART. These might have been the factors responsible
for delayed diagnosis which in turn has led to high early
mortality. Other study results from South Africa showed
that one or more opportunistic diseases and immune re-
constitution inflammatory syndrome were the major
causes of death at early initiation of ART [21].
Lost to follow up was found to be high, 106(14.5 %).
Most of the lost to follow up cases occurred within six
Table 1 Description of demographic and behavioral characteristics
of patients at baseline in Durame and Hosanna hospitals and
Shinshicho and Hossana health centers, 2007–2011, (n= 730)
Variable Number Percent
Sex Male 301 41.2 %
Female 429 58.8 %
Age at start of ART by years 15_24 92 12.6 %
25_34 359 49.2 %
35__44 197 27.0 %
45__54 58 7.9 %
>54+ 24 3.3 %
ART initiated by Years 2007 270 37.0 %
2008 134 18.0 %
2009 160 22.0 %
2010 81 11.0 %
2011 85 12.0 %
Marital status Single 94 12.9 %
Married 415 56.9 %
Separated 51 7.0 %
Divorced 58 8.0 %
Widowed 111 15.2 %
Unknown 1 0.001 %
Level of education Without formal
education
161 22.1 %
Primary 315 43.2 %
Secondary 204 27.9 %
Tertiary 50 6.8 %
Religion Orthodox 176 24.1 %
Muslim 91 12.5 %
Protestant 445 61.0 %
Catholic 18 2.5 %
Residence Urban 374 51.4 %
Rural 354 48.6 %
Unknown 2 0.003 %
Occupation Employed 278 38.1 %
Unemployed 451 61.9 %
Unknown 1 0.001 %
Condition of the husband/wife Healthy 127 19.8 %
Chronically ill 155 24.1 %
Dead 148 23.0 %
Unknown 213 33.1 %
Spouse treatment status Enrolled ART 179 27.8 %
Not Enrolled ART 254 39.4 %
Unknown 212 32.9 %
Table 1 Description of demographic and behavioral characteristics
of patients at baseline in Durame and Hosanna hospitals and
Shinshicho and Hossana health centers, 2007–2011, (n= 730)
(Continued)
Risk behavior at baseline Drink alcohol 178 24.4 %




No use of any
substance
360 49.3 %
Attending HIV related training Yes 358 49 %
No 372 51 %
Understanding HIV prophylaxis Good 356 46 %
Poor 374 54 %
Understanding HIV medication
adherence
Good 311 42 %
Poor 419 58 %
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months of starting ART. This was lower than the na-
tional dropout estimate of 21.3 % from Ethiopia [22].
Moreover, lost to follow up was higher when compared
to other studies in Africa. Studies from Cameroon and
Tanzania reported that 5 and 9.7 % lost in the two years
follow up periods, respectively [17, 18]. The longer fol-
low up period is believed to be the reason for the high
lost to follow up rate in our study. The addictive behav-
ior of the patients, drug side effect, absence of tangible
information on the enrolment of spouses and long
distance travel to take medicines might have discouraged
the patients to miss follow ups. Moreover, the lost cases
in our context had probably been dead but were not
reported due to poor patient tracing and reporting
mechanisms of the recent scaled up services of the study
facilities. The lack of National death registration has lim-
ited the capacity of tracing lost cases for possible con-
firmation of outcome [22].
WHO clinical stage of disease was a strong predictor
of mortality in this study. Patients with advanced WHO
clinical stages III and IV had nearly twice higher risk of
dying during the five years survival as compared with
reference group of WHO clinical stage I. Several studies
from Africa including Ethiopia have shown that ad-
vanced WHO stage III and IV was a strong predictor of
mortality in patients on ART, even after controlling for
CD4 cell count [19, 23–26]. The possible reason for the
higher risk of death in patients with advanced clinical
disease stages III and IV could be the increased suscepti-
bility for contracting opportunistic infections among this
group.
The five years survival analyses result showed that pa-
tients who started ART with lower CD4 cells count had
an increased risk of death compared to those who
started with higher CD4 cell counts. The improved rate
of survival among patients who initiated antiretroviral
therapy at higher CD4 cells count probably can be at-
tributed to multiple factors, including earlier control of
viral replication and viral diversity and a greater im-
munologic benefit [27]. These findings are in line with
numerous study findings from resource-limited settings
showing low baseline CD4 cell count was a major pre-
dictor of death, and waiting ART until the CD4 cell
Table 2 Clinical characteristics of patients in four selected health
facilities of Kembata and Hadiya zones, 2007–2011 (n = 730)
Variables Number Percents
Opportunistic illness





















CPT prophylaxis Present 461 63.2 %
Absent 269 36.8 %
Functional status Working 495 68 %
Bedridden 39 5.4 %
Ambulatory 194 26.6 %
Unknown 2 0.003 %
WHO clinical stage Stage I 101 14.0 %
Stage II 148 20.4 %
Stage III 413 57.0 %
Stage IV 62 8.6 %
Unknown 2 0.003 %
Hemoglobin (g/dl) <10 110 15.1 %
≥10 620 84.9 %
CD4 counts at baseline ≤50 cells/mm3 106 14.5 %
51 - 200 cells/mm3 398 54.5 %
201 - 350 cell/mm3 195 26.7 %
>350 cell/mm3 31 4.2 %
Weight at baseline ≤45 160 21.9 %
46 – 55 329 45.1 %
56 – 65 184 25.2 %
>65 57 7.8 %
Regimen at baseline 1a = d4t-3TC-NVP 268 37.0 %
1b = d4t-3TC-EFV 67 9.3 %
1c = AZT-3TC-NVP 197 27.2 %
1d = AZT-3TC-EFV 51 7.0 %
TDF-3TC_NVP 141 19.5 %
Unknown 6 0.008 %
Regimen adherence Good 675 92.5
Fair 18 2.4
Poor 37 5.1
Table 2 Clinical characteristics of patients in four selected health
facilities of Kembata and Hadiya zones, 2007–2011 (n = 730)
(Continued)
Treatment outcome On treatment 423 57.9 %
Dead 92 12.6 %
Stopped 4 .5 %
Lost 17 2.3 %
Transfer out 109 14.9 %
Drop 85 11.6 %
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count falling below 350 cells/mm3 was associated with
increased morbidity and mortality [28, 29]. Similarly,
findings from the developed world suggested that start-
ing ART at higher CD4 cell counts improved treatment
outcomes and decreases mortality [25, 30]. Moreover, re-
cent three years survival analysis result from Hawassa
referral Hospital of SNNPR, Ethiopia has showed that
patients with CD4 count below 50 cells/mm
3 had higher
risk of death [10].
Hemoglobin values at baseline were strongly associ-
ated with the risk of death. Similar study findings
were reported from Tanzania [18] and Ethiopia [13, 19].
Anemia could be an indicator of advanced disease or
clinical feature of some opportunistic infections which
might aggravate risk of death. Furthermore, anemia can be
a feature of certain opportunistic diseases, like dissemi-
nated mycobacterial infection and parvovirus B19 [31].
Several other etiologic factors may be involved in the de-
velopment of HIV-associated anemia, including micro-
nutrient deficiencies, immunological myelosuppression,
impaired erythropoietin production and blood loss
from intestinal opportunistic disease [31].
Baseline functional status was strongly associated with
five years survival time. The risk of death for those who
started ART at baseline with bedridden functional
status was twice higher than those who started ART
Fig. 1 Progressive change in median weight over the follow up period in four selected health facilities of Kembata and Hadiya zones of SNNPR,
Ethiopia [2007–2011]
Fig. 2 Progressive change in median CD4 Counts over the follow up period in four selected health facilities of Kembata and Hadiya zones of
SNNPR, Ethiopia [2007–2011]
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with working functional status. Similarly, recent study
finding from Hawassa referral Hospital, SNNPR Ethiopia
has showed that patients with bedridden functional status
had higher risk of death as compared to those with work-
ing functional status [13]. However, there is limited data
from Africa trying to explain higher mortality rates among
the patients with functional status. The higher risk of
death among patients with bedridden functional status
could be the increased susceptibility for opportunistic infec-
tions and other clinical complications including bedsore,
thrombosis, malnutrition, chronic illness and anorexia.
Patients with poor regimen adherence had increased
risk of death [HR 2.695, 95 % CI: 1.396–5.203] as com-
pared with those who had good adherence of regimen.
Medication adherence is critically important to achieve
viral suppression and to avoid the emergence of viral re-
sistance. The presence of more than one opportunistic
infection after ART initiation had also an effect on the
five year survival. Those patients diagnosed as having
two or more opportunistic infections after ART initi-
ation, had a much greater likelihood of dying than those
who had no or only one opportunistic infection. Similarly,
numerous study results from different settings have re-
vealed that opportunistic infection after ART initi-
ation had resulted in increased risk of death [16, 22,
32, 33]. The fact that patients develop opportunistic infec-
tions after ART is an indication of treatment failure and
poor immunological response of ART which might lead to
higher mortality. Moreover, in this study opportunistic
infection after ART could be immune reconstitution















1 16 0.98 [0.96, 0.99] 18 0.97 [0.96, 0.98]
3 25 0.94 [0.92, 0.96] 31 0.93 [0.91, 0.95]
6 22 0.91 [0.89, 0.93] 38 0.88 [0.85, 0.90]
12 7 0.90 [0.87, 0.92] 32 0.83 [0.80, 0.85]
24 14 0.87 [0.84, 0.89] 48 0.74 [0.71, 0.78]
36 2 0.87 [0.84, 0.89] 27 0.71 [0.67, 0.74]
48 4 0.85 [0.81, 0.88] 4 0.67 [0.63, 0.71]
60 2 0.83 [0.79, 0.87] 18 0.64 [0.59, 0.69]
Fig. 3 Cumulative survivals for real (death) and worst case (lost) assumptions of patients during follow up periods in four selected health facilities
of Kembata and Hadiya zones of SNNPR, Ethiopia, 2007–2011
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inflammatory syndrome which has been shown to be
one of the causes of mortality in HIV/AIDS patients
on ART [21]. Pulmonary TB infection after ART initi-
ation has statistically significant association with the
risk of death. A study from three specialized hospitals
of Oromia region, Ethiopia, revealed that TB/HIV co-
infected patients had a lower quality of life as compared
with those HIV infected patients without TB infection [34].
Our study findings revealed that CD4 count and
weight were significantly increased after initiation of
ART at five years survival time. Similarly, numerous
study results from different settings revealed that CD4
count and weight of patient were increased after initi-
ation of ART [14, 15, 17].
This five years survival analysis, in both models, sex,
age, body weight, past opportunistic infection, place of
residence, religious affiliation, facilities of care and level
of education, marital status, risk behaviors such smoking
tobacco and use of other substances were not statisti-
cally significant in multivariate analysis. Similar results
were reported in different studies conducted in develop-
ing countries (37, 40, 46_47).
The collection of data from large number of patients,
inclusion of ART services at different health facility
Fig. 4 Cumulative Hazard function for real and worst case assumptions during follow up periods in four selected health facilities of Kembata and
Hadiya zones of SNNPR, Ethiopia, 2007–2011
Fig. 5 Overall model fit of the Cox regression using the Cox-Snell residuals
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Table 4 Bivariate and Multivariate analysis for baseline clinical characteristics of patients in four selected health facilities of Kembata
and Hadiya zones for Death (real case assumptions), 2007 – 2011
Characteristics real case N Bivariate analysis
Hazard ratio7 (95 % CI)
Multivariate analysis
Hazard ratio (95 % CI)
Sex
Female 429 1 1
Male 301 1.69 (1.69, 2.12) 1.22 (0.70, 2.10)
Spouse treatment status
Enrolled ART 179 1 1
Not Enrolled ART 254 2.54 (1.26, 5.13) 1.31 (0.29, 5.98)
Unknown 212 2.88 (1.41, 5.85) 1.32 (0.61, 2.86)
Smoke Tobacco
No 636 1 1
Yes 94 1.70 (1.00, 2.87) 0.40 (0.12, 1.36)
Use other substances
No 631 1 1
Yes 98 1.87 (1.13, 3.09) 1.12 (0.66, 1.54)
Attending HIV related education
No 372 1 1
Yes 358 0.68 (0.44, 1.05) 0.87 (0.66, 1.90)
Understanding HIV prophylaxis
Poor 374 1 1
Good 356 0.70(0.46, 1.06) 0.65 (0.45, 1.89)
Understanding of Adherence to HIV medication
Poor 419 1 1
Good 311 0.68 (0.44, 1.05) 0.68 (0.38, 1.44)
OIs before initiation of ART
No OIs 249 1
Only one OIs 280 1.27 (0.78, 2.07) NA
≥2 OIs 201 0.73 (0.44, 1.23) NA
TB status before initiation of ART
Absent 711 1
Present 19 3.33 (1.54, 7.20) 1.25 (0.68, 1.54)
OIs after initiation of ART
No OIs 534 1 1
Only one OIs 170 2.38 (1.51, 3.75) 1.24 (1.06, 1.89)
≥2OIs 26 10.90 (6.13, 19.37) 3.35 (1.46,7.69)
TB after initiation of ART
Absent 662 1 1
Present 68 1.82 (1.03, 3.22) 1.428 (1.28, 3.39)
Past prophylaxis
Not Received 269 1
Received 461 0.88 (0.59, 1.33) NA
Functional status
Working 495 1 1
Ambulatory 194 2.81 (1.79, 4.41) 1.79 (1.05, 3.07)
Bedridden 39 6.32 (3.42, 11.700) 3.40 (1.61, 7.21)
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levels (hospitals and health centers) as opposed to the
hospital studies from Ethiopia [13, 19, 32], inclusion of
all eligible patient cards from the study facilities and use
of individual level data were some of the strengths of
this study. However, the study has limitations as well,
since secondary data was used for statistical analyses,
exploring a wide range of possible predictors for
treatment outcomes was not possible. Thus, it was
not possible to measure some important predictors
such as nutritional status, viral loads and other important
variables established as predictors of morbidity and mortal-
ity in patients on ART [21]. Retrospective nature of the
study possibly introduces bias as the quality of information
obtained from these finding is highly dependent on the
completeness of patient records. Moreover, these findings
were limited to Ethiopia and the first five years of ART.
Conclusion
The high early mortality have practical implications for
addressing the need to initiate ART early which would
require early diagnosis of HIV and might be addressed
with improved counseling and testing services at facil-
ities with strong community education and mobilization.
The various baseline factors including WHO staging,
CD4 counts, functional status, regimen adherence and
hemoglobin level have significant effect on five years sur-
vival. Substantial efforts need to be made to move patients
into care earlier in their disease progression in order to
obtain the maximum benefit from ART. CD4 counts and
weight of the patients were significantly increased at dif-
ferent follow up period. Health care providers should give
serious attention to the identification of HIV opportunistic
infections during initiation of ART which could contribute
Table 4 Bivariate and Multivariate analysis for baseline clinical characteristics of patients in four selected health facilities of Kembata
and Hadiya zones for Death (real case assumptions), 2007 – 2011 (Continued)
WHO clinical stage
Stage I 101 1 1
Stage II 148 2.32 (0.64, 8.41) NA
Stage III 413 5.06 (1.59, 16.13) 2.01 (1.02, 4.35)
Stage IV 62 8.58 (2.46, 19.87) 2.42 (1.19, 5.86)
Hemoglobin by g/dl
<10 110 1 1
≥10 620 0.17 (0.11, 0.26) 0.22 (0.14, 0.37)
CD4 counts at baseline
<51 cells/mm3 106 1 1
51 –200 cells/mm3 398 0.23 (0.15, 0.35) 0.26 (0.15, 0.45)
201 –350 cell/mm3 195 0.13 (0.07, 0.25) 0.20 (0.09, 0.43)
>350 cell/mm3 31 0.06 (0.01, 0.46) 0.12 (0.02, 0.91)
Weight at baseline
≤45 160 1 1
46 –55 329 0.58 (0.37, 0.93) 0.52 (0.29, 1.93)
56 – 65 184 0.39 (0.21, 0.70) 0.51 (0.28, 1.18)
>65 57 0.24 (0.07, 0.75) 0.55 (0.16, 1.19)
Regimen at baseline
1a = d4t-3TC-NVP 268 1 1
1b = d4t-3TC-EFV 67 0.71 (0.32, 1.58) NA
1c = AZT-3TC-NVP 197 0.55 (0.31, 0.97) 1.63 (0.87, 3.05)
1d = AZT-3TC-EFV 51 0.84 (0.36, 1.98) NA
TDF-3TC_NVP 141 1.39 (0.82, 2.35) NA
Regimen Adherence
Good 675 1 1
Fair 18 4.36 (2.00, 9.50) 1.66 (0.59, 4.62)
Poor 37 5.94 (3.49, 10.14) 2.70 (1.40, 5.20)
OIs Opportunistic infection
NA Not available
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to reducing early death. In conclusion, all people living
with HIV/AIDS should initiate ART as early as possible.
Initiation of ART at the early stages of the disease and be-
fore the deterioration of the functional status of the pa-
tients and before the reduction of CD4 counts and
hemoglobin levels with an intensified health educa-
tion on adherence to ART regimen is recommended.
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